6CQ Stock Chart & Stats
€0.65
-€0.02(-4.01%)
At close: 4:00 PM EDT
€0.65
-€0.02(-4.01%)
Day’s Range― - ―
52-Week Range€0.53 - €1.90
Previous CloseN/A
Volume91.00
Average Volume (3M)561.00
Market Cap
€265.60M
Enterprise Value€1.17K
Total Cash (Recent Filing)€32.87M
Total Debt (Recent Filing)€592.02M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Nov 05, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding355,588,680
10 Day Avg. Volume11
30 Day Avg. Volume561
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.22
Price to Sales (P/S)0.62
P/FCF Ratio10.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.58Price Target Upside143.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€415.81M
Bulls Say, Bears Say
Bulls Say
Operating ImprovementPositive EBIT and EBITDA, together with a gross margin near 48%, show that the core operating model has improved despite bottom-line losses. If maintained, this operating base can support better earnings conversion, reinvestment in brands and stores, and progress toward sustainable profitability.
Positive Operating Cash FlowPositive operating cash flow indicates that Cresco’s ongoing cultivation, manufacturing, wholesale, and retail activities are generating cash before investment needs. This provides an important foundation for funding operations internally, even though the current level remains insufficient to fully offset losses.
Integrated Market PositionCresco’s presence across production, branded products, wholesale distribution, and owned dispensaries gives it multiple routes to market in state-regulated cannabis markets. This integrated model can improve control over product placement, customer access, and product mix as legal markets develop.
Bears Say
Persistent Net LossesThe meaningful net loss shows that operating improvement has not yet translated into bottom-line profitability. Continued losses can restrict internal funding, weaken equity returns, and make the company more dependent on operational gains or external capital to support longer-term expansion.
Elevated LeverageDebt remains high relative to shareholders’ equity while the equity base has declined, reducing financial flexibility. This leverage can increase pressure on cash resources, constrain investment choices, and make it harder for Cresco to absorb prolonged weakness in earnings or regulated-market conditions.
Uneven Revenue And Cash ConversionChoppy revenue over several years and a sharp decline in free cash flow indicate that recent operating improvement has not yet demonstrated consistent financial durability. Unstable sales and cash conversion make planning more difficult and limit confidence in self-funded growth over the next several quarters.
Cresco Labs News
6CQ FAQ
What was Cresco Labs’s price range in the past 12 months?
Cresco Labs lowest stock price was €0.53 and its highest was €1.90 in the past 12 months.
What is Cresco Labs’s market cap?
Cresco Labs’s market cap is €265.60M.
When is Cresco Labs’s upcoming earnings report date?
Cresco Labs’s upcoming earnings report date is Nov 05, 2026 which is in 33 days.
How were Cresco Labs’s earnings last quarter?
Cresco Labs released its earnings results on Aug 06, 2026. The company reported €0.036 earnings per share for the quarter, beating the consensus estimate of -€0.014 by €0.05.
Is Cresco Labs overvalued?
According to Wall Street analysts Cresco Labs’s price is currently Undervalued.
Does Cresco Labs pay dividends?
Cresco Labs does not currently pay dividends.
What is Cresco Labs’s EPS estimate?
Cresco Labs’s EPS estimate is -0.01.
How many shares outstanding does Cresco Labs have?
Cresco Labs has 355,588,680 shares outstanding.
What happened to Cresco Labs’s price movement after its last earnings report?
Cresco Labs reported an EPS of €0.036 in its last earnings report, beating expectations of -€0.014. Following the earnings report the stock price went down -0.513%.
Which hedge fund is a major shareholder of Cresco Labs?
Currently, no hedge funds are holding shares in DE:6CQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cresco Labs Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€1.58 (143.12% Upside)
€1.58 (143.12% Upside)
Blogger Sentiment
Bullish
DE:6CQ Sentiment 67%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth €129.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cresco Labs
Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes, gummies, and pre-rolls under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company offers cannabis flowers under the FloraCal brand; and cannabis oils and variety of bites are available at multiple potency levels under the Mindy’s brand, as well as Loud*r brand. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company is headquartered in Chicago, Illinois.
6CQ Company Deck
6CQ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: management delivered solid Q1 margins and EBITDA from a streamlined cost structure, achieved meaningful operational and licensing wins (PA store expansion, Ohio openings, Kentucky harvest, Texas license) and provided constructive Q2 growth guidance (~+10% revenue). Offsets include near-term revenue headwinds from the planned California exit and Michigan excise tax, ongoing pricing compression, seasonal cash flow timing, and unresolved regulatory details around rescheduling (including the scope and timing of 280E relief). On balance, operational momentum, accretive M&A activity, and licensing progress outweigh the short-term market and regulatory challenges.View all DE:6CQ earnings summaries6CQ Stock 12 Month Forecast
Average Price Target
€1.58
▲(143.12% Upside)